Q4 2025 Halozyme Therapeutics Inc Earnings Call Transcript
Key Points
- Halozyme Therapeutics Inc (HALO) reported a strong financial performance in 2025, with total revenue growth of 38%, reaching a record $1.4 billion.
- The company expanded its portfolio from 2 to 4 subcutaneous drug delivery technologies through strategic acquisitions, enhancing its capabilities and collaboration opportunities.
- Royalty revenue increased by 52% to $868 million, driven by the success of enhanced enabled products like Darzalex subcutaneous, Fesco, and Vyguard Hytrulo.
- The company signed three new enhanced collaboration and licensing agreements, expanding its reach into obesity and inflammatory bowel disease.
- Halozyme Therapeutics Inc (HALO) strengthened its capital structure by issuing convertible notes and upsizing its revolving credit facility, enhancing liquidity and strategic flexibility.
- The company's net income for 2025 was impacted by a $285 million acquired IPR&D expense related to the Surf Bio acquisition.
- GAAP diluted EPS decreased from $3.43 in 2024 to $2.50 in 2025, reflecting the unfavorable impact of the acquired IPR&D expense.
- SG&A expenses increased due to litigation expenses, consulting and professional services, and transaction-related costs.
- The company faces potential challenges with the expiration of its licensing agreement with Johnson & Johnson in 2032, requiring renegotiation to continue the partnership.
- There is uncertainty regarding the regulatory path for converting approved ADCs to subcutaneous delivery with Enhance, which may require additional efficacy and safety trials.
Good afternoon. My name is Alexandra, and I will be your conference operator today. At this time, I would like to welcome everyone to Halozyme's 4th quarter and full year 2025 financial and operating results conference call.
After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press 1 on your telephone keypad. To withdraw your question, press 1 again.
Please note this event is being recorded. I will now turn the call over to Tram Bui, Halozy's Vice President of Investor relations and corporate communications. Please go ahead.
Thank you, operator. Good afternoon and welcome to our fourth quarter in full year 2025 financial and operating results conference call. In addition to the press release issued today after the market closed, you could find a supplementary slide presentation that will be referenced during today's call in the investor relations section of our website.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
